Immunitybio Inc (IBRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunitybio Inc (IBRX) has a cash flow conversion efficiency ratio of 1.356x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.91 Million) by net assets ($-50.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Immunitybio Inc for the company's overall valuation and market capitalisation.
Immunitybio Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Immunitybio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immunitybio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunitybio Inc ranked by their cash flow conversion efficiency. See how well can Immunitybio Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Volvo Car AB (publ.)
ST:VOLCAR-B
|
0.019x |
|
Chord Energy Corp
NASDAQ:CHRD
|
0.070x |
|
Open Text Corp
TO:OTEX
|
0.079x |
|
Hancock Whitney Corp
NASDAQ:HWC
|
0.034x |
|
Perseus Mining Ltd
AU:PRU
|
0.180x |
|
Castellum AB
ST:CAST
|
0.010x |
|
Hunan Yuneng New Energy Battery Material Co. Ltd. A
SHE:301358
|
N/A |
|
HAIDILAO INT.HLDG LTD
F:8HI
|
N/A |
Annual Cash Flow Conversion Efficiency for Immunitybio Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Immunitybio Inc from 2013 to 2024. View current stock price of Immunitybio Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-488.13 Million | $-391.24 Million | 0.802x | +28.05% |
| 2023-12-31 | $-585.94 Million | $-366.76 Million | 0.626x | -16.58% |
| 2022-12-31 | $-449.82 Million | $-337.51 Million | 0.750x | -33.31% |
| 2021-12-31 | $-243.91 Million | $-274.42 Million | 1.125x | -22.37% |
| 2020-12-31 | $-118.49 Million | $-171.72 Million | 1.449x | +214.98% |
| 2019-12-31 | $120.68 Million | $-152.11 Million | -1.260x | -190.36% |
| 2018-12-31 | $146.01 Million | $-63.38 Million | -0.434x | -94.75% |
| 2017-12-31 | $218.84 Million | $-48.78 Million | -0.223x | -69.47% |
| 2016-12-31 | $293.42 Million | $-38.59 Million | -0.132x | -85.04% |
| 2015-12-31 | $356.00 Million | $-25.30 Million | -0.071x | +22.43% |
| 2014-12-31 | $58.42 Million | $-5.35 Million | -0.092x | -139.72% |
| 2013-12-31 | $-2.90 Million | $-668.00K | 0.231x | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more